1 / 32

IN THE NAME OF GOD

IN THE NAME OF GOD. RVO EVALUATION&TREATMENT. ETESAMPOOR MD vitroretinal flowship. Response to questions. Laboratory tests Ophthalmic test Ophthalmic treatments Prognosis How to fallow up. CRVO EVALUATION. SYSTEMIC VASCULAR DISEASE:diabetes mellitus

chaela
Download Presentation

IN THE NAME OF GOD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IN THE NAME OF GOD

  2. RVO EVALUATION&TREATMENT ETESAMPOOR MD vitroretinalflowship

  3. Response to questions • Laboratory tests • Ophthalmic test • Ophthalmic treatments • Prognosis • How to fallow up

  4. CRVO EVALUATION SYSTEMIC VASCULAR DISEASE:diabetes mellitus Hypertension, carotid insufficincy. • OCULAR DISEASES:open angle glacuma, Ischmic optic neuropathy,pseudotumorcerebri Tilted optic nerve head,optic nerve head drusen • HEMATOLOGIC ALTERATION:hyperviscosity Multiple myeloma,blooddyscrasias,anemia&… • INFLAMMATORY/AUTOIMMUNE VASCULITIS: SLE • MEDICATIONS:oralcontraceptives,duretics, Hepatitis B vaccine, • INFECTIOUS VASCULITIS:HIV,syphilis,herpes zoster • OTHER:retrobulbarblock,dehydration,pregnancy

  5. CRVO EVALUATION • SYSTEMIC WORKUP is not indicated in person older than60 years of age with known systemic Vascular risk factors for CRVO. younger patient are more likely to have predispo- Ing conditions resulting in thrombotic disease. • A limited systemic workup may be considered in those with prior occlusion in the fellow eye, prior systemic thrombotic disease,family history of thrombosis,hematologic or rheumatologic .

  6. CRVO EVALUATION:LAB.tests • CBC,ESR,FBS,ANA,ANTIPHOSPHOLIPID Ab fasting plasma homocysteine level. • In bilateral,simaltaneous CRVO or mixed-type retinal vascular occlusions should have detailed evaluation for a hypercogulable condition, as these persons may be at risk for future,non-Ocular thrombotic events.

  7. OPHTHALMIC TEST IN CRVO • Wide-angle FA 30 second after Iv injection of Sodium fluorescein. • classification:perfused[less than 10 disc areas of capillary nonperfusion]non perfused[10 or more disc areas of retinal capillary nonperfusion] indeterminate [intraretinal hemorrhage prevent angiographic determination of perfusion status]. • OCT

  8. THERAPEUTIC OPTIONS IN CRVO • MACULAR EDEMA • Observation • Corticosteroid therapy • Intravitreal anti-VEGF therapy • NEOVASCULARIZATION • Laser photocoagulation • Medical therapy • ALTERNATIVE TREATMEHTS • Chorioretinal venous anastomosis • Tissue plasminogen activator • Surgical treatments:vitrectomy,radial optic neurotomy,

  9. MACULAR EDEMA OBSERVATION Widespread damage to the perifovealcapillarynetwrk has been hypothesized to contribute to the lack of visual recovery.

  10. MACULAR EDEMA CORTICOSTEROID THERAPY • It is believed that corticosteroid maintain anti-Inflammatory effects with modulation of production of cytokines and growth factor including VEGF.steroid are also stabilize blood retinal barrier with reduction in vascular permeability. • Eyes were treated with 1-mg IVTA every 4month for 1 year and observed significant improvement in visual acuity compared to observation. • Primary ocular advers events included cataract formation and elevated Intraocular pressure. • In chronic refractory CME sustained –release intravitrealdexamethasone delivery system,OZURDEX,was approved .

  11. MACULAR EDEMA • Intravitreal anti-VEGF therapy • Combined anti-VEGF and corticosteroid

  12. OCULAR NEOVASCULARIZATION • Laser phothcoagulation • CVOS recommended that PRP be delivered promptly after the development of NVI/NVA but not in eyes with nonperfusedcrvo. • Prophylactic PRP may be done in special risk factors for developing NVI/NVA[male gender, short duration of CRVO,extensive retinal nonperusion,and extensive retinal hemorrhage]

  13. Optociliary shunt

  14. SYSTEMIC MEDICAL CONDITION • Treatment of systemic vascular risk factors, coordination with the internist is strongly recommended • Systemic anticoagulation such as asprin or heparin,cannot prevent or alter the natural history of CRVO but may help prevent nonocular thrombotic events ,especially in individuals with known systemic vascular disease. • Oral pentoxifylline is a potent vasodilator usedin systemic vascular diseases to improve perfusionto occluded vessels and enhance the development ofcollateralcirculation.this drug reduct macular thickening but not change in VA or perfusion status. • Hemodilation increased oxigen supply to the retina. Hemodilution is likely not appropriate for patient with anemia,renal insufficiency ,or pulmonary insuffcieny.

  15. Response to questions BRVO • Laboratory tests • Ophthalmic test • Ophthalmic treatments • Prognosis • How to fallow up

  16. BRVO EVALUATION • Systemic vascular diseases such as aterioscleros Diabetis,smoking,hyperlipidemia,glaucoma, and ocular inflammatory disease. antiphosphlipidAB,elevated plasma homocystein level and low serum folate. • Short axial length • In bilateral cases or cases involving young patients,systemic manifestation of infectious disease,inflammatory or autoimmune condition, neoplasm,orhypercoagulable states may be present.

  17. DIAGNOSTIC WORKUP • PARTICULAR ATTENTION to the history of glaucoma and sign of intraocular inflammation • IN YOUNG:CBC,FBS,prothrombin time/partial thromboplastintime,lipidpanel,homocysteine anticardiolipinAB,protein C/S • IN OLDER than 60,additional workup isnot necessary since the majority are idiopathic or due to hypertension or atherosclerosis.

  18. OPHTHALMIC TEST • F/A For delineate the retinal vascular caharacteristic That may have prognostic significance :macular Leakage and edema,macularischemia,and large Segments of capillary nonperfusion that may Portend neovascularization[ischemic BRVO>5 disc diameters nonperfusion] • In chronic cases ,when the hemorrhages have resolved,microvascular changes on F/Amay provide the only clues of a previous BRVO. • When we have leakage and edema with cystoid involvement of the fovea,but no capillary nonperfusion, the macular edema is the cause of vision loss. • when macular edema is present within the first6 month after a BRVO and there is little or no leakage on F/A,macular ischemia may be the cause of the macular edema and almost always spontaneously resorbs in the first year after occlusion,often with return of vision. • OCT Used to monitor the response to treatment of macular edema and has been used in Place of F/A in some treatment trials for BRVO.

  19. Chronic case of BRVO

  20. TREATMENT OPTIONS IN BRVO • MEDICAL TREATMENT • LASER TREATMENT • STEROID TREATMENT • ANTI-VEGF TREATMENT • FAVOR[ILUVIEN] STUDY • SURGICAL MANAGEMENT[vitrectomy with or Without sheathotomy]

  21. Medical treatment • In most cases anticoagulant therapy has not been shown to be beneficial in either the prevention or the management of BRVO.Sincethes systemic administration of anticoagulants can be associated with systemic complication, and could,intheory,increase the severity of intraretinal hemorrhage occurring in the acute phase,such therapy is not recommended.

  22. Laser treatment

  23. Steroid treatment • Triamcinolone Corticosteroid inhibit the expression of VEGF and reduce macular edema.Significant side-effects,including cataract and Glaucoma. 1mg IVTA every 4 months reduced macular edema but not recommended as first –line therapy and considered in patients where macular grid laser or other therapies are ineffective,as the treatment was found to be relatively safe,especially in pseudophakic eyes. • Dexamethasone implant. • FAVOR[ILUVIEN] sustained-release non-erodable,intravitreal implant for patients with macular edema due to BRVOorCRVO of>3 months,duration in phase 2 trial.

  24. prognosis • BRVO:1/3 to1/2 of patients have return of vision to 20/40 or better without any therapy. 31-41℅of patients with ischemic BRVO developed neovascularization or vitreous hemmorrhage,compared with11℅of patients With nonischemicBRVO.decreased vision for over 1 year as a result of macular edema are much less likely to regain vision spontaneously. When macular edema is present within the first 6 months after a BRVO and there is little or no leakage on FA,macular ischemia may be the cause of the macular edema .this edema always resorbs in the first year after the occlusion, often with return of vision.

  25. CRVO prognosis • A perfused CRVO have better initial and final VA • A nonperfused CRVO have poor VA and large areas of retinal capillary nonperfusion were significant factors associated with an increased risk of developing NVI/NVA. • Initial VA was highly correlated with degree of nonperfusion and prognosis.

  26. Follow up • In CRVO eye with initial acuity of 20/40 or better were generally examined every1-2 MO for 6 MO,then annually if stable. • Eye with initial acuity worse than 20/200 were Seen monthly for the initial 6 MO,then bimonthly For the next 6 MO. • Eyes with 20/50 and20/200 have an intermediate risk of developing NVI/NVA and were also typically examined monthly for the first 6 MO.

  27. BRVO FOLLOW UP • In BRVO initially,patents followed closely every MO or2 MO for macular edema and/or NVE. • Once macular edema stabilized or resolved interval can be extended to 3-6 MO or even longer for stable chonic cases. • Patients with previously untreated retinal nonperfusion >5disc diameters followd at closer intervals[3 months]due to the increased risk for neovascular complication.

  28. THE END

More Related